C1q-Alectinib Complexation Disrupts Tight Junction Integrity to Enable Paracellular Brain Penetration

Target: CLDN5, OCLN Composite Score: 0.455 Price: $0.46 Citation Quality: Pending molecular biology Status: proposed Variant of C1q-Alectinib Complexation Facilitates Brain Penet

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.455

Top 81% of 984 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

C+ Mech. Plausibility 15% 0.50 Top 77%

F Evidence Strength 15% 0.00 Top 50%

F Novelty 12% 0.00 Top 50%

F Feasibility 12% 0.00 Top 50%

F Impact 12% 0.00 Top 50%

C+ Druggability 10% 0.50 Top 63%

C+ Safety Profile 8% 0.50 Top 58%

C+ Competition 6% 0.50 Top 80%

C+ Data Availability 5% 0.50 Top 67%

C+ Reproducibility 5% 0.50 Top 68%

Evidence

4 supporting | 5 opposing

Citation quality: 0%

Debates

2 sessions B+

Avg quality: 0.75

Convergence

0.21 F 30 related hypothesis share this target

From Analysis:

Does Alectinib truly bind C1q directly with high affinity, or is this an experimental artifact?

The fundamental premise remains unvalidated despite extensive mechanistic speculation. Independent validation using purified proteins and orthogonal binding assays is essential before pursuing mechanistic studies. This determines whether any C1q-related effects are direct or indirect. Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e (Analysis: SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

C1q-Alectinib Complexation Enhances CNS Penetration via Microglial C1qR-Mediated Uptake and Redistribution

Score: 0.415 | Target: C1QBP

Transferrin-Alectinib Conjugation Enhances Blood-Brain Barrier Transport via Transferrin Receptor-Mediated Endocytosis

Score: 0.406 | Target: TFRC

C1q-Alectinib Complexation Facilitates Brain Penetration via Receptor-Mediated Transcytosis

Score: 0.145 | Target: %s

Direct C1q Binding Enables FcγR-Independent Complement Activation on Tumor Cells

Score: 0.138 | Target: %s

Human Serum Albumin-Mediated Displacement Creates False-Positive C1q Binding Signals

Score: 0.136 | Target: %s

C1q Binding Reflects Broader Kinase Inhibitor Promiscuity Rather Than Specific Complement Targeting

Score: 0.124 | Target: %s

Alectinib Binds Mitochondrial C1q-like Proteins (C1QDC1) Rather Than Circulating C1q

Score: 0.122 | Target: %s

C1q Binding Analysis Across ALK Inhibitor Chemical Series Would Resolve Specificity

Score: 0.115 | Target: %s

→ View full analysis & all 9 hypotheses

Description

This hypothesis proposes that C1q protein forms stable complexes with alectinib through electrostatic interactions between C1q's globular head domains and alectinib's aminopyridine moiety. Rather than facilitating receptor-mediated transcytosis, the C1q-alectinib complex specifically targets claudin-5 and occludin proteins at blood-brain barrier tight junctions. The complement C1q component binds to exposed negatively charged residues on claudin-5's extracellular loops, particularly glutamate and aspartate residues in the second extracellular domain. This binding triggers conformational changes that weaken claudin-5 homotypic interactions and disrupt the tight junction seal.

...

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

9 citations 9 with PMID Validation: 0% 4 supporting / 5 opposing

✓ For (4)

No supporting evidence

No opposing evidence

(5) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 6CLIN 3GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Alectinib demonstrates superior CNS penetration ve…	Supporting	MECH	-	-	-	-	PMID:28797065	-
C1q receptors (CD93, CD91) are expressed at blood-…	Supporting	MECH	-	-	-	-	PMID:29251563	-
CD93 deficiency impairs CNS drug delivery, suggest…	Supporting	CLIN	-	-	-	-	PMID:31133878	-
C1q is expressed in choroid plexus and blood-CSF b…	Supporting	MECH	-	-	-	-	PMID:29251563	-
C1q is primarily synthesized locally in the brain …	Opposing	MECH	-	-	-	-	PMID:29251563	-
CD93 mediates cell adhesion and leukocyte transmig…	Opposing	CLIN	-	-	-	-	PMID:31133878	-
C1q is a ~460 kDa complex unlikely to traverse BBB…	Opposing	CLIN	-	-	-	-	PMID:29251563	-
Alectinib's BBB penetration is explicable by …	Opposing	MECH	-	-	-	-	PMID:28797065	-
Other ALK inhibitors achieve CNS penetration witho…	Opposing	MECH	-	-	-	-	PMID:28797065	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 4

Alectinib demonstrates superior CNS penetration versus earlier-generation ALK inhibitors with brain:plasma rat…▼

Alectinib demonstrates superior CNS penetration versus earlier-generation ALK inhibitors with brain:plasma ratio ~0.5-0.8

PMID:28797065

C1q receptors (CD93, CD91) are expressed at blood-brain barrier and theoretically could mediate transcellular …▼

C1q receptors (CD93, CD91) are expressed at blood-brain barrier and theoretically could mediate transcellular transport

PMID:29251563

CD93 deficiency impairs CNS drug delivery, suggesting a role for C1q receptors in brain penetration

PMID:31133878

C1q is expressed in choroid plexus and blood-CSF barrier, potentially enabling receptor-mediated transcytosis …▼

C1q is expressed in choroid plexus and blood-CSF barrier, potentially enabling receptor-mediated transcytosis mechanisms

PMID:29251563

✗ Opposing Evidence 5

C1q is primarily synthesized locally in the brain by microglia and astrocytes rather than crossing the BBB fro…▼

C1q is primarily synthesized locally in the brain by microglia and astrocytes rather than crossing the BBB from circulation

PMID:29251563

CD93 mediates cell adhesion and leukocyte transmigration, not vectorial drug transport - no established preced…▼

CD93 mediates cell adhesion and leukocyte transmigration, not vectorial drug transport - no established precedent for C1qR-mediated transcytosis

PMID:31133878

C1q is a ~460 kDa complex unlikely to traverse BBB even when bound to alectinib - drug-C1q complexation would …▼

C1q is a ~460 kDa complex unlikely to traverse BBB even when bound to alectinib - drug-C1q complexation would increase molecular size

PMID:29251563

Alectinib's BBB penetration is explicable by physicochemical properties (logD, molecular weight ~482 Da, moder…▼

Alectinib's BBB penetration is explicable by physicochemical properties (logD, molecular weight ~482 Da, moderate lipophilicity) without active transport

PMID:28797065

Other ALK inhibitors achieve CNS penetration without C1q binding - lorlatinb has excellent brain penetration d…▼

Other ALK inhibitors achieve CNS penetration without C1q binding - lorlatinb has excellent brain penetration despite different structure

PMID:28797065

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Analysis Wrap | 4 rounds | 2026-04-19 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses: Alectinib-C1q Binding Validation

Hypothesis 1: Alectinib Indirectly Modulates C1q via ALK Signaling in Tumor-Associated Macrophages

Description: Rather than binding C1q directly, alectinib may suppress C1q production through ALK-independent inhibition of NF-κB signaling in tumor-associated macrophages (TAMs), thereby reducing complement-mediated pro-tumor inflammation.

Target Gene/Protein: ALK (Anaplastic Lymphoma Kinase) / NFKB1 / C1QA-C1QC

Supporting Evidence:

C1q is produced by macrophages and myeloid cells in the tumor microenvironment

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Alectinib-C1q Binding Hypotheses

Hypothesis 1: Indirect Modulation via ALK Signaling in TAMs

Specific Weaknesses in Evidence

The proposed mechanism requires an implausibly specific chain of events: alectinib must cross tumor cell membranes, inhibit ALK in tumor cells, produce a signal that travels to TAMs, and there suppress NF-κB to reduce C1q transcription. This multi-step cascade lacks direct evidence linking ALK inhibition in tumor cells to C1q suppression in TAMs. The evidence cited for NF-κB cross-talk with complement regulation (PMID:28813421) descri

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Drug Development Perspective: Alectinib-C1q Binding Analysis

Executive Summary

The critical evaluation correctly identifies that orthogonal validation is essential before mechanistic elaboration. From a drug development standpoint, the core question isn't just "does alectinib bind C1q?" but rather "so what if it does?" This analysis addresses the druggability question, existing chemical matter, competitive landscape, safety considerations, and realistic investigation costs/timelines.